NTRB

Nutriband Inc. (NTRB) - Q1 2025 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended April 30, 2025. Nutriband Inc. is a Nevada corporation focused on developing transdermal pharmaceutical products, primarily utilizing its proprietary AVERSA abuse-deterrent technology. The company operates through two main segments: Pocono Pharmaceuticals (contract manufacturing and sales of goods) and 4P Therapeutics (research and development of pharmaceutical products). The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.

Key Financial Metrics

Note: Q1 2024 cash balance shown is the ending balance for that period for comparison. Total debt includes notes payable and secured borrowing liabilities.

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased by approximately 63% year-over-year, driven entirely by the Pocono Pharmaceuticals segment. The 4P Therapeutics segment generated no revenue in Q1 2025, compared to zero in Q1 2024, as the company shifted focus to product development.
• Reduced Net Loss: The net loss narrowed by $509,208 (27% decrease) compared to Q1 2024. This improvement was primarily due to a significant reduction in non-cash stock-based compensation expenses and lower research and development (R&D) costs.
• Expense Reductions:
  • R&D Expenses: Decreased from $974,535 to $683,426, attributed to reduced labor costs.
  • Selling, General & Administrative (SG&A): Decreased from $1,079,728 to $982,052, largely due to lower equity-based compensation.
• Interest Income: Increased significantly from $18 to $30,508, resulting from higher interest rates on cash balances generated from the April 2024 equity financing.

Outlook, Risks, and Management Commentary

• Going Concern: Management believes substantial doubt regarding the company's ability to continue as a going concern is alleviated. They project sufficient funds to operate for the next 12 months based on current cash ($2.96M) and working capital, alongside a $5M credit line facility with a related party.
• Product Development: The company is advancing its lead product, AVERSA Fentanyl, in partnership with Kindeva Drug Delivery. An amended agreement in February 2025 reduced the remaining budget for NDA submission to $3.2 million and added a $3.0 million milestone payment upon FDA approval.
• Legal Proceedings: The company is a defendant in a lawsuit filed by Joseph Gunnar, LLC and Lucosky Brookman LLP in New York State Supreme Court. Plaintiffs seek over $500,000 in damages plus punitive damages regarding the termination of an engagement letter. The company has filed counterclaims seeking $2 million in damages. The case is currently in the discovery stage.
• Internal Controls: Management disclosed that disclosure controls and procedures are not effective due to material weaknesses, including a lack of segregation of duties and reliance on third-party consultants. Remediation efforts are underway.

Investor Verification Checklist

• Cash Burn Rate: Verify the sustainability of the $2.96M cash balance against the reported operating cash burn of ~$1.34M per quarter.
• Legal Exposure: Monitor the status of the Gunnar/LB lawsuit and the potential impact of the $2M counterclaim or the $500k+ plaintiff claim on future liquidity.
• Revenue Concentration: Confirm the stability of the Pocono Pharmaceuticals segment, which currently accounts for 100% of revenue, while the core R&D pipeline (4P Therapeutics) generates no revenue.
• Internal Control Remediation: Assess the timeline and effectiveness of management's plan to address the material weaknesses in internal controls over financial reporting.
• Related Party Transactions: Review the terms of the $5M credit line facility with the related party and the $106,528 secured borrowing liability tied to a bankruptcy claim.